Corrigendum: Gene therapy clinical trials worldwide to 2017: An update (The Journal of Gene Medicine, (2018), 20, 5, (e3015), 10.1002/jgm.3015);Gene therapy clinical trials worldwide to 2017: An update

Journal of Gene Medicine

Volumn 20, Issue 5, 2018, Pages

  Ginn, Samantha L ^a   Amaya, Anais K ^a   Alexander, Ian E ^a   Edelstein, Michael ^b   Abedi, Mohammad R ^c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b Centre on Global Health Security   (United Kingdom)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

clinical trials; database; gene therapy; The Journal of Gene Medicine; worldwide

Indexed keywords

ALIPOGENE TIPARVOVEC; AXICABTAGENE CILOLEUCEL; GENDICINE; LUXTURNA; STRIMVELIS; TISAGENLECLEUCEL T; VIRUS VECTOR; VORETIGENE NEPARVOVEC; YESCARTA;

CANCER IMMUNOTHERAPY; CARDIOVASCULAR GENE THERAPY; CELL THERAPY; CHIMERIC ANTIGEN RECEPTOR NATURAL KILLER CELL IMMUNOTHERAPY; CLINICAL PRACTICE; CLINICAL TRIAL; DNA REPAIR; GENE DELIVERY SYSTEM; GENE EDITING; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; GENE TRANSFER; GENETIC DISORDER; GEOGRAPHIC DISTRIBUTION; HUMAN; MALIGNANT NEOPLASM; MONOGENIC DISORDER; NONHUMAN; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE; TREATMENT INDICATION; TREATMENT RESPONSE; TREND STUDY; ADOPTIVE IMMUNOTHERAPY; CLINICAL TRIAL (TOPIC); GENETICS; GLOBAL HEALTH; NEOPLASM; OUTCOME ASSESSMENT; PROCEDURES;

CLINICAL TRIALS AS TOPIC; GENETIC THERAPY; GLOBAL HEALTH; HUMANS; IMMUNOTHERAPY, ADOPTIVE; NEOPLASMS; OUTCOME ASSESSMENT (HEALTH CARE);

EID: 85048049494     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.3124     Document Type: Erratum

References (167)

1. Rosenberg SA, Aebersold P, Cornetta K, et al. Gene transfer into humans – immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med. 1990;323:570-578.
2. Ginn SL, Alexander IE, Edelstein ML, et al. Gene therapy clinical trials worldwide to 2012 – an update. J Gene Med. 2013;15:65-77.
3. Edelstein ML, Abedi MR, Wixon J. Gene therapy clinical trials worldwide to 2007 – an update. J Gene Med. 2007;9:833-842.
4. Edelstein ML, Abedi MR, Wixon J, et al. Gene therapy clinical trials worldwide 1989–2004 – an overview. J Gene Med. 2004;6:597-602.
5. Gaspar HB, Cooray S, Gilmour KC, et al. Long-term persistence of a polyclonal T cell repertoire after gene therapy for X-linked severe combined immunodeficiency. Sci Transl Med. 2011;3. 97ra79
6. Hacein-Bey-Abina S, Hauer J, Lim A, et al. Efficacy of gene therapy for X-linked severe combined immunodeficiency. N Engl J Med. 2010;363:355-364.
7. Aiuti A, Roncarolo MG. Ten years of gene therapy for primary immune deficiencies. Hematology 2009 – the Education Program of the American Society of Hematology. Education Program. 2009;2009:682-689.
8. Gaspar HB, Cooray S, Gilmour KC, et al. Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction. Sci Transl Med. 2011;3. 97ra80
9. Cavazzana-Calvo M, Payen E, Negre O, et al. Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia. Nature. 2010;467:318-322.
10. Boztug K, Schmidt M, Schwarzer A, et al. Stem-cell gene therapy for the Wiskott-Aldrich syndrome. N Engl J Med. 2010;363:1918-1927.
11. Bainbridge JW, Smith AJ, Barker SS, et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med. 2008;358:2231-2239.
12. Maguire AM, Simonelli F, Pierce EA, et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med. 2008;358:2240-2248.
13. Maguire AM, High KA, Auricchio A, et al. Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial. Lancet. 2009;374:1597-1605.
14. Nathwani AC, Tuddenham EG, Rangarajan S, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med. 2011;365:2357-2365.
15. Cartier N, Hacein-Bey-Abina S, Bartholomae CC, et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science. 2009;326:818-823.
16. Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006;314:126-129.
17. Robbins PF, Morgan RA, Feldman SA, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 2011;29:917-924.
18. Kalos M, Levine BL, Porter DL, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011;3. 95ra73
19. Porter DL, Levine BL, Kalos M, et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365:725-733.
20. Sadelain M. CAR therapy: the CD19 paradigm. J Clin Invest. 2015;125:3392-3400.
21. Ramos CA, Heslop HE, Brenner MK. CAR-T cell therapy for lymphoma. Annu Rev Med. 2016;67:165-183.
22. Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371:1507-1517.
23. Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6. 224ra225
24. Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368:1509-1518.
25. Brentjens RJ, Davila ML, Riviere I, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013;5. 177ra138
26. Riviere I, Sadelain M. Chimeric antigen receptors: a cell and gene therapy perspective. Mol Ther. 2017;25:1117-1124.
27. Zhang C, Wang Z, Yang Z, et al. Phase I escalating-dose trial of CAR-T therapy targeting CEA+ metastatic colorectal cancers. Mol Ther. 2017;25:1248-1258.
28. Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science. 2013;342:1432-1433.
29. Emily Whitehead Foundation. Celebrating 5 Years Cancer Free! 2017. http://emilywhiteheadfoundation.org/celebrating-5-years-cancer-free/ [7 August 2017].
30. US Food and Drug Administration. FDA Approval Brings First Gene Therapy to the United States. CAR T-Cell Therapy Approved to Treat Certain Children and Young Adults with B-Cell Acute Lymphoblastic Leukemia. US Food and Drug Administration Newsroom Website: Press Release 30 August 2017. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm574058.htm [3 April 2018].
31. Ahmed N, Brawley V, Hegde M, et al. HER2-specific chimeric antigen receptor-modified virus-specific T cells for progressive glioblastoma: a phase 1 dose-escalation trial. JAMA Oncol. 2017;3:1094-1101.
32. Brown CE, Alizadeh D, Starr R, et al. Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N Engl J Med. 2016;375:2561-2569.
33. O'Rourke DM, Nasrallah MP, Desai A, et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med. 2017;9. eaaa0984
34. Alton EW, Armstrong DK, Ashby D, et al. Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Respir Med. 2015;3:684-691.
35. Thrasher AJ, Williams DA. Evolving gene therapy in primary immunodeficiency. Mol Ther. 2017;25:1132-1141.
36. Wang X, Riviere I. Clinical manufacturing of CAR T cells: foundation of a promising therapy. Mol Ther Oncolytics. 2016;3. 16015
37. Bordignon C, Notarangelo LD, Nobili N, et al. Gene therapy in peripheral blood lymphocytes and bone marrow for ADA- immunodeficient patients. Science. 1995;270:470-475.
38. Aiuti A, Roncarolo MG, Naldini L. Gene therapy for ADA-SCID, the first marketing approval of an ex vivo gene therapy in Europe: paving the road for the next generation of advanced therapy medicinal products. EMBO Mol Med. 2017;9:737-740.
39. Yla-Herttuala S. ADA-SCID gene therapy endorsed by European Medicines Agency for marketing authorization. Mol Ther. 2016;24:1013-1014.
40. Carbonaro DA, Zhang L, Jin X, et al. Preclinical demonstration of lentiviral vector-mediated correction of immunological and metabolic abnormalities in models of adenosine deaminase deficiency. Mol Ther. 2014;22:607-622.
41. Braun CJ, Boztug K, Paruzynski A, et al. Gene therapy for Wiskott-Aldrich syndrome – long-term efficacy and genotoxicity. Sci Transl Med. 2014;6. 227ra233
42. Hacein-Bey Abina S, Gaspar HB, Blondeau J, et al. Outcomes following gene therapy in patients with severe Wiskott-Aldrich syndrome. JAMA. 2015;313:1550-1563.
43. De Ravin SS, Wu X, Moir S, et al. Lentiviral hematopoietic stem cell gene therapy for X-linked severe combined immunodeficiency. Sci Transl Med. 2016;8. 335ra357
44. Morris EC, Fox T, Chakraverty R, et al. Gene therapy for Wiskott-Aldrich syndrome in a severely affected adult. Blood. 2017;130:1327-1335.
45. Biffi A, Montini E, Lorioli L, et al. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science. 2013;341. 1233158
46. Biffi A. Hematopoietic stem cell gene therapy for storage disease: current and new indications. Mol Ther. 2017;25:1155-1162.
47. Eichler F, Duncan C, Musolino PL, et al. Hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy. N Engl J Med. 2017;377:1630-1638.
48. Ribeil JA, Hacein-Bey-Abina S, Payen E, et al. Gene therapy in a patient with sickle cell disease. N Engl J Med. 2017;376:848-855.
49. Negre O, Eggimann AV, Beuzard Y, et al. Gene therapy of the beta-hemoglobinopathies by lentiviral transfer of the beta(A(T87Q))-globin gene. Hum Gene Ther. 2016;27:148-165.
50. Cavazzana M, Antoniani C, Miccio A. Gene therapy for beta-hemoglobinopathies. Mol Ther. 2017;25:1142-1154.
51. Mueller C, Gernoux G, Gruntman AM, et al. 5 Year expression and neutrophil defect repair after gene therapy in alpha-1 antitrypsin deficiency. Mol Ther. 2017;25:1387-1394.
52. George LA, Ragni MV, Samelson-Jones BJ, et al. Preliminary results from a phase 1/2 dose escalation trial of an investigational AAV-mediated gene therapy for hemophilia A. American Society of Hematology 59th Annual Meeting and Exposition. Online Conference Proceedings; 9 December 2017. https://ash.confex.com/ash/2017/webprogram/Paper108679.html [30 January 2018].
53. Nathwani AC, Reiss UM, Tuddenham EG, et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med. 2014;371:1994-2004.
54. Nienhuis AW, Nathwani AC, Davidoff AM. Gene therapy for hemophilia. Mol Ther. 2017;25:1163-1167.
55. George LA, Sullivan SK, Giermasz A, et al. Hemophilia B gene therapy with a high-specific-activity factor IX variant. N Engl J Med. 2017;377:2215-2227.
56. Bennett J. Taking stock of retinal gene therapy: looking back and moving forward. Mol Ther. 2017;25:1076-1094.
57. Bennett J, Wellman J, Marshall KA, et al. Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial. Lancet. 2016;388:661-672.
58. Constable IJ, Pierce CM, Lai CM, et al. Phase 2a randomized clinical trial: safety and post hoc analysis of subretinal rAAV.sFLT-1 for wet age-related macular degeneration. E. Biol Med. 2016;14:168-175.
59. Rakoczy EP, Lai CM, Magno AL, et al. Gene therapy with recombinant adeno-associated vectors for neovascular age-related macular degeneration: 1 year follow-up of a phase 1 randomised clinical trial. Lancet. 2015;386:2395-2403.
60. US Food and Drug Administration. FDA Approves Novel Gene Therapy to Treat Patients with a Rare Form of Inherited Vision Loss. US Food and Drug Administration Newsroom Website: Press Release 19 December 2017. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm589467.htm [3 April 2018].
61. Monahan P, Walsh CE, Powell JS, et al. Update on a phase 1/2 open-label trial of BAX335, an adeno-associated virus 8 (AAV8) vector-based gene therapy program for hemophilia B. Proceedings of the XXV International Society on Thrombosis and Haemostasis Conference. North Carolina, USA: Carrboro; 2015;13(Suppl 2): LB010):87.
62. Mendell JR, Al-Zaidy S, Shell R, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med. 2017;377:1713-1722.
63. Abeona Therapeutics. Abeona Therapeutics Receives Regulatory Approval to Initiate Clinical Trial in Australia with ABO-102 Gene Therapy For Patients with MPS IIIA: Clinical Trial Notification (CTN) Enables Initiation at 3rd Global Site and Accelerates Enrollment in the ABO-102 MPS IIIA Gene Therapy Program. Abeona Therapeutics: Press Release 9 May 2017. https://globenewswire.com/news-release/2017/05/09/980972/0/en/Abeona-Therapeutics-Receives-Regulatory-Approval-to-Initiate-Clinical-Trial-in-Australia-with-ABO-102-Gene-Therapy-For-Patients-with-MPS-IIIA.html [3 April 2018].
64. Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377:2531-2544.
65. Clement N, Grieger JC. Manufacturing of recombinant adeno-associated viral vectors for clinical trials. Mol Ther Methods Clin Dev. 2016;3. 16002
66. Baruteau J, Waddington SN, Alexander IE, et al. Gene therapy for monogenic liver diseases: clinical successes, current challenges and future prospects. J Inherit Metab Dis. 2017;40:497-517.
67. Capecchi MR. Altering the genome by homologous recombination. Science. 1989;244:1288-1292.
68. Russell DW, Hirata RK. Human gene targeting by viral vectors. Nat Genet. 1998;18:325-330.
69. Barzel A, Paulk NK, Shi Y, et al. Promoterless gene targeting without nucleases ameliorates haemophilia B in mice. Nature. 2015;517:360-364.
70. Sharma R, Anguela XM, Doyon Y, et al. In vivo genome editing of the albumin locus as a platform for protein replacement therapy. Blood. 2015;126:1777-1784.
71. Greer KL, Lochmuller H, Flanigan K, et al. Targeted exon skipping to correct exon duplications in the dystrophin gene. Mol Ther Nucleic Acids. 2014;e155:3.
72. Kinali M, Arechavala-Gomeza V, Feng L, et al. Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol. 2009;8:918-928.
73. Lundstrom K. Special issue: Gene therapy with emphasis on RNA interference. Virus. 2015;7:4482-4487.
74. Jiang L, Frederick JM, Baehr W. RNA interference gene therapy in dominant retinitis pigmentosa and cone-rod dystrophy mouse models caused by GCAP1 mutations. Front Mol Neurosci. 2014;7:25.
75. Fire A, Xu S, Montgomery MK, et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998;391:806-811.
76. Tabernero J, Shapiro GI, LoRusso PM, et al. First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov. 2013;3:406-417.
77. Barata P, Sood AK, Hong DS. RNA-targeted therapeutics in cancer clinical trials: current status and future directions. Cancer Treat Rev. 2016;50:35-47.
78. Cornu TI, Mussolino C, Cathomen T. Refining strategies to translate genome editing to the clinic. Nat Med. 2017;23:415-423.
79. Couzin J. Nobel Prize in Physiology or Medicine. Method to silence genes earns loud praise. Science. 2006;314:34.
80. Cirak S, Arechavala-Gomeza V, Guglieri M, et al. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet. 2011;378:595-605.
81. Voit T, Topaloglu H, Straub V, et al. Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study. Lancet Neurol. 2014;13:987-996.
82. Bengtsson NE, Seto JT, Hall JK, et al. Progress and prospects of gene therapy clinical trials for the muscular dystrophies. Hum Mol Genet. 2016;25:R9-R17.
83. Finkel RS, Mercuri E, Darras BT, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med. 2017;377:1723-1732.
84. Chamberlain JR, Chamberlain JS. Progress toward gene therapy for Duchenne muscular dystrophy. Mol Ther. 2017;25:1125-1131.
85. US Food and Drug Administration. FDA Grants Accelerated Approval to First Drug for Duchenne Muscular Dystrophy. US Food and Drug Administration Newsroom Website: Press Release 19 September 2016; https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm521263.htm [30 January 2018].
86. Aartsma-Rus A, Krieg AMFDA. approves eteplirsen for Duchenne muscular dystrophy: the next chapter in the eteplirsen saga. Nucleic Acid Ther. 2017;27:1-3.
87. Aartsma-Rus A. FDA Approval of nusinersen for spinal muscular atrophy makes 2016 the year of splice modulating oligonucleotides. Nucleic Acid Ther. 2017;27:67-69.
88. Moscou MJ, Bogdanove AJ. A simple cipher governs DNA recognition by TAL effectors. Science. 2009;326:1501.
89. Boch J, Scholze H, Schornack S, et al. Breaking the code of DNA binding specificity of TAL-type III effectors. Science. 2009;326:1509-1512.
90. Beerli RR, Segal DJ, Dreier B, et al. Toward controlling gene expression at will: specific regulation of the erbB-2/HER-2 promoter by using polydactyl zinc finger proteins constructed from modular building blocks. Proc Natl Acad Sci U S A. 1998;95:14628-14633.
91. Kim YG, Cha J, Chandrasegaran S. Hybrid restriction enzymes: zinc finger fusions to Fok I cleavage domain. Proc Natl Acad Sci U S A. 1996;93:1156-1160.
92. Baker M. Gene-editing nucleases. Nat Methods. 2012;9:23-26.
93. Tebas P, Stein D, Tang WW, et al. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med. 2014;370:901-910.
94. Reardon S. Leukaemia success heralds wave of gene-editing therapies. Nature. 2015;527:146-147.
95. Qasim W, Zhan H, Samarasinghe S, et al. Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. Sci Transl Med. 2017;9. eaaj2013
96. Jinek M, Chylinski K, Fonfara I, et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 2012;337:816-821.
97. Cong L, Ran FA, Cox D, et al. Multiplex genome engineering using CRISPR/Cas systems. Science. 2013;339:819-823.
98. Mali P, Yang L, Esvelt KM, et al. RNA-guided human genome engineering via Cas9. Science. 2013;339:823-826.
99. Ishino Y, Shinagawa H, Makino K, et al. Nucleotide sequence of the iap gene, responsible for alkaline phosphatase isozyme conversion in Escherichia coli, and identification of the gene product. J Bacteriol. 1987;169:5429-5433.
100. Barrangou R, Horvath P. A decade of discovery: CRISPR functions and applications. Nat Microbiol. 2017;2. 17092
101. Hsu PD, Lander ES, Zhang F. Development and applications of CRISPR-Cas9 for genome engineering. Cell. 2014;157:1262-1278.
102. Reardon S. Gene-editing record smashed in pigs. Nature. News 6 October 2015; http://www.nature.com/news/gene-editing-record-smashed-in-pigs-1.18525 [3 April 2018].
103. Niu D, Wei H-J, Lin L, et al. Inactivation of porcine endogenous retrovirus in pigs using CRISPR-Cas9. Science. 2017;357:1303-1307.
104. Cyranoski D. CRISPR gene-editing tested in a person for the first time. Nature. 2016;539:479.
105. US National Library of Medicine, Clinical Trials Website. http://www.clinicaltrials.gov [5 December 2017].
106. Kemaladewi DU, Maino E, Hyatt E, et al. Correction of a splicing defect in a mouse model of congenital muscular dystrophy type 1A using a homology-directed-repair-independent mechanism. Nat Med. 2017;23:984-989.
107. Chen X, Goncalves MA. Engineered viruses as genome editing devices. Mol Ther. 2016;24:447-454.
108. Yin H, Xue W, Chen S, et al. Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nat Biotechnol. 2014;32:551-553.
109. Liang P, Xu Y, Zhang X, et al. CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes. Protein Cell. 2015;6:363-372.
110. Servick K. First US team to gene-edit human embryos revealed. Science News doi: 10.1126/science.aan7170. http://www.sciencemag.org/news/2017/07/first-us-team-gene-edit-human-embryos-revealed [Day Month Year].
111. Ma H, Marti-Gutierrez N, Park SW, et al. Correction of a pathogenic gene mutation in human embryos. Nature. 2017;548:413-419.
112. Lanphier E, Urnov F, Haecker SE, et al. Don't edit the human germ line. Nature. 2015;519:410-411.
113. Baltimore D, Berg P, Botchan M, et al. Biotechnology. A prudent path forward for genomic engineering and germline gene modification. Science. 2015;348:36-38.
114. Weisberg SM, Badgio D, Chatterjee A. A CRISPR new world: attitudes in the public toward innovations in human genetic modification. Front Public Health. 2017;5:117.
115. Cyranoski D, Reardon S. Chinese scientists genetically modify human embryos: rumours of germline modification prove true – and look set to reignite an ethical debate. Nat News 22 April 2015. http://www.nature.com/news/chinese-scientists-genetically-modify-human-embryos-1.17378 [3 April 2018].
116. Callaway E. Doubts raised about CRISPR gene-editing study in human embryos. Nat News 21 August 2017. https://www.nature.com/news/doubts-raised-about-crispr-gene-editing-study-in-human-embryos-1.22547#/ref-link-2 [3 April 2018].
117. Yin H, Kanasty RL, Eltoukhy AA, et al. Non-viral vectors for gene-based therapy. Nat Rev Genet. 2014;15:541-555.
118. Semple SC, Akinc A, Chen J, et al. Rational design of cationic lipids for siRNA delivery. Nat Biotechnol. 2010;28:172-176.
119. Cullis PR, Hope MJ. Lipid nanoparticle systems for enabling gene therapies. Mol Ther. 2017;25:1467-1475.
120. Lachelt U, Wagner E. Nucleic acid therapeutics using polyplexes: a journey of 50 years (and beyond). Chem Rev. 2015;115:11043-11078.
121. Kay MA, Glorioso JC, Naldini L. Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med. 2001;7:33-40.
122. Verma IM, Weitzman MD. Gene therapy: twenty-first century medicine. Annu Rev Biochem. 2005;74:711-738.
123. Warren L, Manos PD, Ahfeldt T, et al. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell. 2010;7:618-630.
124. Zhou W, Freed CR. Adenoviral gene delivery can reprogram human fibroblasts to induced pluripotent stem cells. Stem Cells. 2009;27:2667-2674.
125. Kim D, Kim C-H, Moon J-I, et al. Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. Cell Stem Cell. 2009;4:472-476.
126. Yu J, Hu K, Smuga-Otto K, et al. Human induced pluripotent stem cells free of vector and transgene sequences. Science. 2009;324:797-801.
127. Park A, Hong P, Won ST, et al. Sendai virus, an RNA virus with no risk of genomic integration, delivers CRISPR/Cas9 for efficient gene editing. Mol Ther Methods Clin Dev. 2016;3. 16057
128. Wang M, Zuris JA, Meng F, et al. Efficient delivery of genome-editing proteins using bioreducible lipid nanoparticles. Proc Natl Acad Sci U S A. 2016;113:2868-2873.
129. Staahl BT, Benekareddy M, Coulon-Bainier C, et al. Efficient genome editing in the mouse brain by local delivery of engineered Cas9 ribonucleoprotein complexes. Nat Biotechnol. 2017;35:431-434.
130. Ortinski PI, O'Donovan B, Dong X, et al. Integrase-deficient lentiviral vector as an all-in-one platform for highly efficient CRISPR/Cas9-mediated gene editing. Mol Ther Methods Clin Dev. 2017;5:153-164.
131. Petris G, Casini A, Montagna C, et al. Hit and go CAS9 delivered through a lentiviral based self-limiting circuit. Nat Commun. 2017;8. 15334
132. National Institutes of Health Research, UK Clinical Trials Gateway. http://www.ukctg.nihr.ac.uk [5 December 2017].
133. Belgian Scientific Institute of Public Health, Belgian Biosafety Server – Gene Therapy Clinical Trials in Belgium. http://www.biosafety.be/GT/regulatory/GTtrials.html [5 December 2017].
134. University Medical Centre Freiburg and the German Cochrane Center, German Clinical Trials Register. https://www.drks.de/drks_web [5 December 2017].
135. Swiss Expert Committee for Biosafety, Gene Therapy. http://www.efbs.admin.ch/en/topics/gene-therapy.html [5 December 2017].
136. European Medicines Agency, EU Clinical Trials Register. https://www.clinicaltrialsregister.eu [5 December 2017].
137. EU Joint Research Centre, Deliberate Release and Placing on the EU Market of GMOs – GMO Register. http://gmoinfo.jrc.ec.europa.eu/gmo_browse.aspx [5 December 2017].
138. Australain New Zealand Clinical Trials Registry. http://www.anzctr.org.au/default.aspx [5 December 2017].
139. The Chinese Clinical Test Registration Center, Chinese Clinical Trial Registry. http://www.chictr.org.cn/enIndex.aspx [5 December 2017].
140. National Institutes of Public Health Japan, NIPH Clinical Trials Search. http://rctportal.niph.go.jp/en [5 December 2017].
141. World Health Organisation, International Clinincal Trials Registry Platform. http://apps.who.int/trialsearch [5 December 2017].
142. Morrow MP, Kraynyak KA, Sylvester AJ, et al. Clinical and immunologic biomarkers for histologic regression of high-grade cervical dysplasia and clearance of HPV16 and HPV18 after immunotherapy. Clin Cancer Res. 2018;24:276-294.
143. Trimble CL, Morrow MP, Kraynyak KA, et al. Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial. Lancet. 2015;386:2078-2088.
144. REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL) (REVEAL 1). US National Library of Medicine ClinicalTrials.gov Identifier: NCT03185013. 7 November 2017. https://clinicaltrials.gov/ct2/show/NCT03185013 [30 January 2018].
145. Masemann D, Boergeling Y, Ludwig S. Employing RNA viruses to fight cancer: novel insights into oncolytic virotherapy. Biol Chem. 2017;398:891-909.
146. Park GT, Choi KC. Advanced new strategies for metastatic cancer treatment by therapeutic stem cells and oncolytic virotherapy. Oncotarget. 2016;7:58684-58695.
147. Russell SJ, Peng KW. Oncolytic virotherapy: a contest between apples and oranges. Mol Ther. 2017;25:1107-1116.
148. Amgen. FDA Approves IMLYGIC™ (Talimogene Laherparepvec) As First Oncolytic Viral Therapy In The US. AMGEN website: Press Release 27 October 2015. http://www.amgen.com/media/news-releases/2015/10/fda-approves-imlygic-talimogene-laherparepvec-as-first-oncolytic-viral-therapy-in-the-us/ [30 January, 2018].
149. Yla-Herttuala S, Baker AH. Cardiovascular gene therapy: past, present, and future. Mol Ther. 2017;25:1095-1106.
150. Zhang L, Nolan E, Kreitschitz S, et al. Enhanced delivery of naked DNA to the skin by non-invasive in vivo electroporation. Biochim Biophys Acta. 2002;1572:1-9.
151. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126:663-676.
152. Schwartz SD, Regillo CD, Lam BL, et al. Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt's macular dystrophy: follow-up of two open-label phase 1/2 studies. Lancet. 2015;385:509-516.
153. Higuchi A, Kumar SS, Benelli G, et al. Stem cell therapies for reversing vision loss. Trends Biotechnol. 2017;35:1102-1117.
154. Klassen H. Stem cells in clinical trials for treatment of retinal degeneration. Expert Opin Biol Ther. 2016;16:7-14.
155. Qi X, Pay SL, Yan Y, et al. Systemic injection of RPE65-programmed bone marrow-derived cells prevents progression of chronic retinal degeneration. Mol Ther. 2017;25:917-927.
156. Reardon S, Cyranoski D. Japan stem-cell trial stirs envy. Nature. 2014;513:287-288.
157. Garber K. RIKEN suspends first clinical trial involving induced pluripotent stem cells. Nat Biotechnol. 2015;33:890-891.
158. Mandai M, Watanabe A, Kurimoto Y, et al. Autologous induced stem-cell-derived retinal cells for macular degeneration. N Engl J Med. 2017;376:1038-1046.
159. Normile D. iPS cell therapy reported safe. Science. 2017;355:1109-1110.
160. Shi Y, Inoue H, Wu JC, et al. Induced pluripotent stem cell technology: a decade of progress. Nat Rev Drug Discov. 2017;16:115-130.
161. Somia N, Verma IM. Gene therapy: trials and tribulations. Nat Rev Genet. 2000;1:91-99.
162. Sack BK, Herzog RW. Evading the immune response upon in vivo gene therapy with viral vectors. Curr Opin Mol Ther. 2009;11:493-503.
163. Martino AT, Basner-Tschakarjan E, Markusic DM, et al. Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood. 2013;121:2224-2233.
164. Bender E. Gene therapy: industrial strength. Nature. 2016;537:S57-S59.
165. Orkin SH, Reilly P. MEDICINE. Paying for future success in gene therapy. Science. 2016;352:1059-1061.
166. Couzin-Frankel J. Supply of promising T cell therapy is strained. Science. 2017;356:1112-1113.
167. Nirenberg MW. Will society be prepared? Science. 1967;157:633.